Volume : 09, Issue : 09, September – 2022



Authors :

Shahsawar, Khalid, Mahmood ul Hassan, Muhammad Idrees Khan, Adnan khan

Abstract :

Introduction: Currently, coronary stenting has been recommended as a primary strategy of revascularization for patients with coronary artery disease.
Objective: To compare outcome of MACE after DEB Vs DES in treatment of patients with In stent restenosis (ISR) presented with chest pain
Methodology: The current study was Quasi experimental study carried out at the Department of Cardiology, MTI-HMC Peshawar for duration of six months from 21 April, 2021 to 21 Nov, 2021. In this study, 94 patients in DEB group and 94 patients in DES group were followed for 06 months to look for development of MACE. All data was collected through a well-defined proforma. Data was entered on computer software SPSS version 22.
Results: In DEB group, 52 (55.3%) male patients and 42 (44.7%) female patients were recorded whereas in DES group, 57 (60.6%) male patients while 37 (39.4%) female patients were recorded. In DEB group, 15 (16.0%) patients were recorded with MACE whereas in DES group, 38 (40.4%) patients were recorded with MACE.
Conclusion: Our study demonstrated that DEB is supervisor to DES in the in-stent restenosis treatment and a smaller number of major adverse cardiovascular events (MACE) in managing CAD, and therefore DEB may be considered as an alternative choice for treatment of CAD patients admitted in our setting in order to reduce mortality and morbidity associated with restenosis in such patients.
Key words: Coronary Artery Disease, Drug-Eluting Stents, Drug Eluting Balloon, Restenosis

Cite This Article:

Please cite this article in press Shahsawar et al, Comparative Outcomes Of Mace After Drug Eluting Balloon vs. Drug Eluting Stent In Treatment Of In-Stent Restenosis (ISR) Patients Presented With Acute Coronary Syndrome., Indo Am. J. P. Sci, 2022; 09(9).

Number of Downloads : 10


1. Cui K-Y, Lyu S-Z, Zhang M, Song X-T, Yuan F, Xu F. Drug-eluting balloon versus new-generation drug-eluting stent for the treatment of in-stent restenosis: an updated systematic review and meta-analysis. Chin Med J. 2018;131(05):600-7.
2. Paramasivam G, Devasia T, Jayaram A, Razak A, Rao MS, Vijayvergiya R, et al. In-stent restenosis of drug-eluting stents in patients with diabetes mellitus: Clinical presentation, angiographic features, and outcomes. Anatolian journal of cardiology. 2020;23(1):28.
3. Goel SS, Dilip Gajulapalli R, Athappan G, Philip F, Gupta S, Murat Tuzcu E, et al. Management of drug eluting stent in‐stent restenosis: A systematic review and meta‐analysis. Catheter Cardiovasc Interv. 2016;87(6):1080-91.
4. Zheng J-F, Guo T-T, Tian Y, Wang Y, Hu X-Y, Chang Y, et al. Clinical characteristics of early and late drug-eluting stent in-stent restenosis and mid-term prognosis after repeated percutaneous coronary intervention. Chin Med J. 2020;133(22):2674-81.
5. Ferri LA, Jabbour RJ, Giannini F, Benincasa S, Ancona M, Regazzoli D, et al. Safety and efficacy of rotational atherectomy for the treatment of undilatable underexpanded stents implanted in calcific lesions. Catheter Cardiovasc Interv. 2017;90(2):E19-E24.
6. Wang G, Zhao Q, Chen Q, Zhang X, Tian L, Zhang X. Comparison of drug-eluting balloon with repeat drug-eluting stent for recurrent drug-eluting stent in-stent restenosis. Coron Artery Dis. 2019;30(7):473.
7. Varghese MJ, Bhatheja S, Baber U, Kezbor S, Chincholi A, Chamaria S, et al. Intravascular brachytherapy for the management of repeated multimetal-layered drug-eluting coronary stent restenosis. Circ Cardiovasc Interv. 2018;11(10):e006832.
8. Gao L, Wang Y-B, Jing J, Zhang M, Chen Y-D. Drug-eluting balloons versus new generation drug-eluting stents for the management of in-stent restenosis: an updated meta-analysis of randomized studies. Journal of Geriatric Cardiology: JGC. 2019;16(6):448.
9. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O’Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349(14):1315-23.
10. Stone GW, Ellis SG, Cox DA, Hermiller J, O’Shaughnessy C, Mann JT, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350(3):221-31.
11. Kedhi E, Joesoef KS, McFadden E, Wassing J, Van Mieghem C, Goedhart D, et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. The Lancet. 2010;375(9710):201-9.
12. Harjai KJ, Kondareddy S, Pinkosky B, Harjai N, Orshaw P, Boura J. Everolimus‐Eluting Stents Versus Sirolimus‐or Paclitaxel‐Eluting Stents: Two‐Year Results from the Guthrie Health Off‐Label Stent (GHOST) Registry. J Interv Cardiol. 2013;26(2):153-62.
13. Alfonso F, Byrne RA, Rivero F, Kastrati A. Current treatment of in-stent restenosis. J Am Coll Cardiol. 2014;63(24):2659-73.
14. Theodoropoulos K, Mennuni MG, Dangas GD, Meelu OA, Bansilal S, Baber U, et al. Resistant in‐stent restenosis in the drug eluting stent era. Catheter Cardiovasc Interv. 2016;88(5):777-85.
15. Marquis-Gravel G, Matteau A, Potter BJ, Gobeil F, Noiseux N, Stevens L-M, et al. Impact of Paclitaxel-Eluting Balloons Compared to Second-Generation Drug-Eluting Stents for of In-Stent Restenosis in a Primarily Acute Coronary Syndrome Population. Arq Bras Cardiol. 2017;109:277-83.
16. Siontis GC, Stefanini GG, Mavridis D, Siontis KC, Alfonso F, Pérez-Vizcayno MJ, et al. Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis. The Lancet. 2015;386(9994):655-64.
17. Alfonso F, Scheller B. Management of recurrent in-stent restenosis: onion skin full metal jacket? EuroIntervention: journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 2013;9(7):781-5.
18. Alfonso F, García J, Pérez-Vizcayno M-J, Hernando L, Hernandez R, Escaned J, et al. New stent implantation for recurrences after stenting for in-stent restenosis: implications of a third metal layer in human coronary arteries. J Am Coll Cardiol. 2009;54(11):1036-8.
19. Kubo S, Kadota K, Otsuru S, Hasegawa D, Shigemoto Y, Habara S, et al. Optimal treatment of recurrent restenosis lesions after drug-eluting stent implantation for in-stent restenosis lesions. Eurointervention: Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 2013;9(7):788-96.
20. Kawamoto H, Ruparelia N, Latib A, Miyazaki T, Sato K, Mangieri A, et al. Drug-coated balloons versus second-generation drug-eluting stents for the management of recurrent multimetal-layered in-stent restenosis. JACC Cardiovasc Interv. 2015;8(12):1586-94.
21. Auer J, Stone GW. Routine angiographic surveillance for risk stratification in PCI-treated patients: fact or fiction? : Oxford University Press; 2015. p. 71-4.